The Medicines Co. nets $400M nod for UTI antibacterial treatment

Vabomere's peak sales will hit $400 million in 2028, one analyst predicts.

Doctors treating patients with complicated urinary tract infections will soon have a new tool in their arsenal with the FDA’s Tuesday approval for Vabomere, a combination of the antibacterial meropenem and vaborbactam, a component to combat bacterial resistance.

The Medicines Company won approval for the new antibacterial, which is set for launch in the fourth quarter, the company said in a statement. The drug works by addressing bacteria that produce the KPC enzyme, which make up the majority of carbapenem-resistant Enterobacteriaceae that the CDC has called an “urgent antimicrobial resistance threat.”

“We look forward to a successful U.S. launch of Vabomere, leveraging our established, fully dedicated commercial infrastructure, and to expanding Vabomere into other global markets,” CEO Clive Meanwell said in a statement. The company will announce the med’s price at launch time, Leerink Partners analyst Joseph Schwartz wrote in a note to clients.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Medicines Company won a priority review with the med, and the antibacterial’s status as a Qualified Infectious Disease Product guarantees an additional 5 years of exclusivity, according to the pharma. Exclusivity on the antibacterial is expected to stretch into 2031. Schwartz, meanwhile, sees the product eventually racking up peak sales of about $400 million in 2028, but in the near term, he’s predicting $8 million in Q4 sales.

As Schwartz pointed out, Vabomere’s label is favorable for The Medicines Company; it includes specific pathogens  and microbiological data that “could facilitate product adoption by infectious disease physicians.” Among those pathogens: Klebsiella pneumoniae, Escherichia coli, and Enterobacter cloacae, which “collectively are believed to cause the majority of Carbapenem-resistant Enterobacteriaceae (CRE) infections,” he wrote, adding, “we expect revenues to increase in not only the cUTI market but also in CRE infections.”

It’s been a big week for the drugmaker, which over the weekend delivered new data on next-gen PCSK9 candidate inclisiran. Results showed “robust lowering” of LDL cholesterol levels at both the six-month and one-year marks, Jefferies analyst Biren Amin wrote to clients, adding that company management “continues to explore strategic options around partnering while moving forward” with both the phase 3 and cardiovascular outcomes studies it announced in April.